BIA 6-512 |
(E)-RESVERATROL |
NSC-327430 |
RESVERATROL |
BIA-6-512 |
3,5,4'-TRIHYDROXY-TRANS-STILBENE |
Drug Indications | antidiabetic,antineoplastic agent |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | for treatment of herpes simplex virus 1 |
Drug Categories | ribonucleotide reductases, antagonists & inhibitors |
Drug Categories | antioxidants |
Drug Categories | antimutagenic agents |
Drug Categories | antiplatelet agents |
Drug Categories | benzopyrans |
Drug Categories | chromones |
Drug Categories | compounds used in a research, industrial, or household setting |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | flavones |
Drug Categories | flavonoids |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | polyphenols |
Drug Categories | pyrans |
Drug Categories | stilbenes |
Drug Categories | vasodilating agents |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Trial Name | Resveratrol |
Novel drug target | Established target |
Trial Name | SRT501 |
n/a |
Trial Name | SRT501 |
Novel drug target | Established target |
Trial Name | Resveratrol |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Direct Interaction? | False |
RESVERATROL | DrugBank Drug Name |
501-36-0 | CAS Number |
Co-Balamin | Drug Brand |
Drug Type | small molecule |
Drug Groups | investigational |
Drug Categories | analgesics |
Drug Indications | for treatment of herpes simplex virus 1 |
Drug Class | small molecule |
FDA Approval | not approved |
C1215 | NCI drug code |
CHEMBL165 | ChEMBL Drug ID |
RESVERATROL | GuideToPharmacology Ligand Name |